摘要
目的分析布地奈德治疗小儿呼吸道合胞病毒(RSV)感染相关喘息的效果和对患儿血清炎性因子的影响。方法选择2016年6月至2017年6月在我院就诊的RSV感染相关喘息患儿84例,按照随机分配原则将其分为对照组和观察组,各42例。对照组给予常规治疗,观察组则在对照组基础上给予布地奈德雾化吸入治疗。比较两组患儿的治疗效果、治疗前、后的血清炎性因子水平、肺功能及出院后6个月、1年的喘息发作和哮喘发生情况。结果观察组患儿的治疗总有效率高于对照组,差异具有统计学意义(P<0.05);治疗前,两组IL-4、IL-12、IL-6、CRP、IgE、CD3^+、CD4^+、CD8^+水平、CD4^+/CD8^+、FEV1及FEV1/FVC比较,差异均无统计学意义(P>0.05);治疗后,两组患儿IL-4、IL-12、IL-6、CRP、IgE、CD3^+、CD4^+、CD8^+水平及CD4^+/CD8^+均改善,且观察组优于对照组,差异具有统计学意义(P<0.05);治疗后,两组患儿的FEV1及FEV1/FVC均高于治疗前,且观察组高于对照组,差异具有统计学意义(P<0.05);观察组患儿出院后6个月、1年的喘息发作人数少于对照组,且哮喘发生率低于对照组,差异具有统计学意义(P<0.05)。结论布地奈德治疗小儿RSV感染相关喘息的效果显著,有效改善患儿血清炎性因子水平、临床症状,促进肺功能恢复,并且降低患儿喘息发作几率,值得推广。
Objective To analyze the effect of budesonide on respiratory syncytial virus (RSV) infection-related wheezing in children and its influence on serum inflammatory factors.Methods A total of 84 children with RSV infection-related wheezing in our hospital from June 2016 to June 2017 were selected and divided into control group and observation group according to the principle of random distribution, with 42 cases in each group.The control group received routine treatment, and the observation group was treated with budesonide aerosol inhalation therapy on the basis of the control group.The treatment effects, levels of serum inflammatory factors, lung function before and after treatment, wheezing attack and incidence of asthma at 6 months and 1 year after discharge of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group, the difference was statistically significant (P<0.05).Before treatment, there were no significant differences in the levels of IL-4, IL-12, IL-6, CRP, IgE, CD3^+, CD4^+, CD8^+, CD4^+/CD8^+, FEV1 and FEV1/FVC between the two groups (P>0.05).After treatment, the levels of IL-4, IL-12, IL-6, CRP, IgE, CD3^+, CD4^+, CD8^+ and CD4^+/CD8^+ in the two groups improved, and those in the observation group were better than the control group, the differences were statistically significant (P<0.05).After treatment, FEV1 and FEV1/FVC of the two groups were higher than those before treatment, and those in the observation group were higher than the control group, the differences were statistically significant (P<0.05).The numbers of wheezing attacks at 6 months and 1 year after discharge in the observation group were less than those in the control group, and the incidences of asthma were lower than those in the control group, the differences were statistically significant (P<0.05).Conclusion Budesonide is effective in the treatment of children with RSV infection-related wheezing.It can effectively improve levels of serum inflammatory factors, clinical symptoms and promote lung function recovery, and decrease the rate of wheezing in children, which is worth promoting.
作者
刘竟
LIU Jing(the People's Hospital of Wuqi County,Yan'an 717600,China)
出处
《临床医学研究与实践》
2019年第15期73-75,共3页
Clinical Research and Practice
关键词
布地奈德
呼吸道合胞病毒
感染
喘息
血清炎性因子
budesonide
respiratory syncytial virus
infection
wheezing
serum inflammatory factor
